Molecular Partners Management
Management criteria checks 2/4
Molecular Partners' CEO is Patrick Amstutz, appointed in Jan 2004, has a tenure of 20.83 years. total yearly compensation is CHF1.05M, comprised of 36.8% salary and 63.2% bonuses, including company stock and options. directly owns 1.99% of the company’s shares, worth CHF3.54M. The average tenure of the management team and the board of directors is 3.3 years and 4.6 years respectively.
Key information
Patrick Amstutz
Chief executive officer
CHF 1.0m
Total compensation
| CEO salary percentage | 36.8% |
| CEO tenure | 20.8yrs |
| CEO ownership | 2.0% |
| Management average tenure | 3.3yrs |
| Board average tenure | 4.6yrs |
Recent management updates
Recent updates
We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate
Sep 10
We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation
Apr 11Is Molecular Partners (VTX:MOLN) In A Good Position To Invest In Growth?
Jan 09Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation
Sep 08Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023
Jun 23What You Need To Know About The Molecular Partners AG (VTX:MOLN) Analyst Downgrade Today
Aug 31Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans
May 09Upgrade: Analysts Just Made A Substantial Increase To Their Molecular Partners AG (VTX:MOLN) Forecasts
Dec 26We're Hopeful That Molecular Partners (VTX:MOLN) Will Use Its Cash Wisely
Jun 24Molecular Partners AG (VTX:MOLN) Could Be Less Than A Year Away From Profitability
Mar 09Analysts Just Made A Major Revision To Their Molecular Partners AG (VTX:MOLN) Revenue Forecasts
Feb 10Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans
Jan 21How Much Of Molecular Partners AG (VTX:MOLN) Do Insiders Own?
Dec 17
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -CHF 63m |
| Jun 30 2024 | n/a | n/a | -CHF 58m |
| Mar 31 2024 | n/a | n/a | -CHF 59m |
| Dec 31 2023 | CHF 1m | CHF 385k | -CHF 62m |
| Sep 30 2023 | n/a | n/a | -CHF 60m |
| Jun 30 2023 | n/a | n/a | -CHF 62m |
| Mar 31 2023 | n/a | n/a | -CHF 50m |
| Dec 31 2022 | CHF 1m | CHF 383k | CHF 118m |
| Sep 30 2022 | n/a | n/a | CHF 117m |
| Jun 30 2022 | n/a | n/a | CHF 118m |
| Mar 31 2022 | n/a | n/a | CHF 106m |
| Dec 31 2021 | CHF 1m | CHF 380k | -CHF 64m |
| Sep 30 2021 | n/a | n/a | -CHF 67m |
| Jun 30 2021 | n/a | n/a | -CHF 72m |
| Mar 31 2021 | n/a | n/a | -CHF 66m |
| Dec 31 2020 | CHF 1m | CHF 380k | -CHF 63m |
| Sep 30 2020 | n/a | n/a | -CHF 53m |
| Jun 30 2020 | n/a | n/a | -CHF 48m |
| Mar 31 2020 | n/a | n/a | -CHF 43m |
| Dec 31 2019 | CHF 930k | CHF 363k | -CHF 36m |
| Sep 30 2019 | n/a | n/a | -CHF 37m |
| Jun 30 2019 | n/a | n/a | -CHF 38m |
| Mar 31 2019 | n/a | n/a | -CHF 38m |
| Dec 31 2018 | CHF 909k | CHF 346k | -CHF 37m |
| Sep 30 2018 | n/a | n/a | -CHF 27m |
| Jun 30 2018 | n/a | n/a | -CHF 18m |
| Mar 31 2018 | n/a | n/a | -CHF 24m |
| Dec 31 2017 | CHF 885k | CHF 344k | -CHF 25m |
Compensation vs Market: Patrick's total compensation ($USD1.18M) is above average for companies of similar size in the Swiss market ($USD834.44K).
Compensation vs Earnings: Patrick's compensation has increased whilst the company is unprofitable.
CEO
Patrick Amstutz (49 yo)
20.8yrs
Tenure
CHF 1,047,000
Compensation
Dr. Patrick Amstutz, Ph.D. is a Co-Founder of Molecular Partners AG and has been its Chief Executive Officer since November 2016 and serves as its Member of Management Board since 2004. Dr. Amstutz serves...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 20.8yrs | CHF 1.05m | 1.99% CHF 3.5m | |
| Co-Founder | 20.8yrs | no data | 2.08% CHF 3.7m | |
| Senior VP of Finance | 5.3yrs | no data | no data | |
| COO & Member of Management Board | 2.3yrs | no data | 0.070% CHF 123.8k | |
| Executive VP of People & Community and Member of Management Board | 2.9yrs | no data | 0.062% CHF 110.8k | |
| Senior Vice President of Research & Technology | 3.7yrs | no data | no data | |
| Senior Vice President of Investor Relations | no data | no data | no data | |
| General Counsel | 2yrs | no data | no data | |
| Strategic Consultant | 5.3yrs | no data | no data | |
| Senior Vice President of Research & Early Development | 2.8yrs | no data | no data | |
| Chief Medical Officer | 1.3yrs | no data | no data |
3.3yrs
Average Tenure
52yo
Average Age
Experienced Management: MOLN's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 7.1yrs | CHF 1.05m | 1.99% CHF 3.5m | |
| Independent Non Executive Director | 10.5yrs | CHF 135.00k | 0.040% CHF 70.9k | |
| Independent Chairman of the Board | 7.1yrs | CHF 295.00k | 0.073% CHF 129.8k | |
| Independent Director | 4.6yrs | CHF 125.00k | 0.0095% CHF 16.9k | |
| Independent Director | 3.6yrs | CHF 125.00k | no data | |
| Independent Director | 4.6yrs | CHF 135.00k | 0.0095% CHF 16.9k | |
| Independent Director | 4.6yrs | CHF 130.00k | 0.0095% CHF 16.9k | |
| Independent Director | 3.6yrs | CHF 133.00k | no data |
4.6yrs
Average Tenure
59yo
Average Age
Experienced Board: MOLN's board of directors are considered experienced (4.6 years average tenure).